title: [Vinblastine treatment for extensive non-X histiocytosis (xanthoma disseminatum)].
abstract: BACKGROUND
  Xanthoma disseminatum is a non-Langerhans histiocyte proliferation, described by Montgomery in 1938. This rare entity is characterized by skin and mucous membrane xanthomatosis, associated with diabetes insipidus and normal lipid metabolism. In this case report, vinblastine produced the regression of the lesions.
  
  
  METHODS
  A 51 year-old man presented in 1999 with a four-year history of progressive xanthomatous papulonodular lesions of his trunk, axillary and inguinal folds, neck and face (leonin facies). Treatment with thalidomide for 6 months was ineffective. A rapid extension of the lesions to the pharynx, larynx and trachea with dyspnea occurred and required a tracheotomy. Histopathological study showed a dense histiocytic infiltrate within the upper and mid dermis with Touton giant cells and inflammatory cells. The histiocyte cells were positive for CD68. Neither lungs nor hypophysis were involved. A treatment with 6 cures of cyclophosphamide was insufficient. Vinblastine therapy (32 cycles: 0.1 mg/kg/cycle) produced a spectacular regression of the mucous-cutaneous papulonodular lesions leaving cheloid scars. The patient required a transitory tracheotomy and a bilateral commissuroplasty.
  
  
  CONCLUSIONS
  Prognosis of xanthoma disseminatum is in related to the mucous membrane manifestations (50 p. 100 of cases) and involvement of the upper respiratory tract. The response to any form of therapy in xanthoma disseminatum is unsatisfactory. Surgical excision or laser therapy can improve physical and functional aspects but the evolution is characterized by very frequent relapses. Treatment with antimitotic drugs seems to be ineffective in many cases. In our patient, vinblastine induced a spectacular regression of mucocutaneous lesions without neurologic toxicity. To our knowledge, this is the first report of vinblastine efficacy in this rare and severe disorder.
authors.affiliation: Service de Dermatologie, Hôpital Bichat, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Pruvost
authors.forename: C
authors.initials: C
authors.lastname: Picard-Dahan
authors.forename: B
authors.initials: B
authors.lastname: Bonnefond
authors.forename: M
authors.initials: M
authors.lastname: Grossin
authors.forename: P
authors.initials: P
authors.lastname: Gehanno
authors.forename: P
authors.initials: P
authors.lastname: Souteyrand
authors.forename: B
authors.initials: B
authors.lastname: Crickx
authors.forename: S
authors.initials: S
authors.lastname: Belaich
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D006644:Histiocytes / Q000473:pathology; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine